insights_auto
Why is AIM down 3,33%?
Dive Deeperchevron_right
AIM:NYSEAMERICAN
AIM ImmunoTech Inc
USDÂ 0,12
arrow_downward
-3,33%(-0,0040) 1D
20 Nov., 13:19:54 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AIM...
Open
USDÂ 0,12
High
USDÂ 0,13
Low
USDÂ 0,12
Mkt. cap
4,63Â m.
Avg. vol.
541,66Â k
Volume
735,58Â k
52-wk high
USDÂ 1,88
52-wk low
USDÂ 0,12
EPS
-USDÂ 2,46
Beta
1,32
Shares outstanding
39,92Â m.
No. of employees
20
Open
USDÂ 0,12
High
USDÂ 0,13
Low
USDÂ 0,12
Mkt. cap
4,63Â m.
Avg. vol.
541,66Â k
Volume
735,58Â k
52-wk high
USDÂ 1,88
52-wk low
USDÂ 0,12
EPS
-USDÂ 2,46
Beta
1,32
Shares outstanding
39,92Â m.
No. of employees
20
News stories
From web sources and news partners
Investing.com UK
·
1 dag gelede
aim immunoTech CEO buys $2,680 in company stock By Investing.com
Investing.com Canada
·
2 dae gelede
Form 8K AIM ImmunoTech Inc For: 18 November By Investing.com
Investing.com
·
3 dae gelede
aim immunoTech CEO Equels buys $5,130 in common stock
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees20
Founded1966
HeadquartersPhiladelphia, Pennsilvanië, Verenigde State van Amerika
SectorHealth Care
Industry-
Websiteaimimmuno.com